Overview
- Late October 2026 Radical Numerics announced that its Omnii-1 AI model redesigned parts of a bacteriophage and that the resulting phage mixture was administered to a patient with an antibiotic‑resistant infection under a doctor‑led compassionate‑use program.
- The company says laboratory tests showed the AI‑designed cocktail eliminated bacteria taken from the patient before treatment, but it has not published methods, safety data, or whether the patient improved.
- Omnii-1 focused on editing the phage’s receptor‑binding tail fiber to change which bacterial surface proteins the virus recognizes rather than writing whole new genomes, a technical approach Radical Numerics says speeds matching to a patient’s strain.
- Experts cite earlier academic work that used AI to create bacteriophages in the lab and warn that moving AI‑designed biological agents into people demands independent peer review, clear safety testing, and stricter oversight to limit dual‑use risks.
- If verified, the step could shorten the time to find tailored phages for drug‑resistant infections and change care for some patients, but broad clinical use will depend on transparent data, regulatory review, and demonstrated safety and effectiveness.